Independently validated.
Rigorously tested.
Aceso Cold Plasma has been evaluated across five independent research institutions — including Wake Forest Institute of Regenerative Medicine, MedStar Georgetown Research Institute, and the US Army CCDC CBC — demonstrating consistent antimicrobial activity and a favorable safety profile at the treatment durations tested. Characterization of tissue effects is ongoing.
5
Independent research institutions
4
Completed investigational studies
14+
Pathogen species tested including ESKAPE strains
0
Adverse effects on healthy host cells observed at treatment durations tested
Four completed studies.
Consistent results.
Each study was independently conducted and funded through the US Air Force SBIR Phase II program. Together they establish a comprehensive evidence base across wound healing, disinfection, burn care, and chemical decontamination.
In Vivo Wound Healing Study
This study evaluated the effect of Aceso Cold Plasma (ACP) on full-thickness skin wounds in a mouse model, comparing treated wounds against untreated controls across multiple treatment durations over a 12-day observation period.
Key findings
Reduced wound contraction. ACP treatment significantly reduced wound contraction compared to untreated controls, with longer treatment durations showing greater effect.
Accelerated re-epithelization. Plasma-treated wounds showed measurably faster re-epithelization and improved formation of both epidermal and dermal layers confirmed by histological analysis.
Favorable cytotoxicity profile in investigational studies. Extended and intense treatments beyond the anticipated optimal level showed negligible cytotoxicity at the durations tested — supporting the development of treatment plans within a defined therapeutic window. Further characterization is ongoing.
Enhanced collagen production. The 240-second treatment resulted in more collagen production in the dermis and faster transition from fibroblast proliferation to maturation.
"The APG is a practical, portable, hand-held CAP device that has the capability of generating a safe and effective therapeutic plasma for enhancing healing of full-thickness skin wounds in both clinical settings and on the field."
Dr. Anthony Atala, MD · Wake Forest Institute of Regenerative Medicine
Antimicrobial Efficacy — Microbiology Study
This study assessed the antimicrobial efficacy of Aceso Cold Plasma against a broad panel of clinically relevant pathogens, including antibiotic-resistant ESKAPE organisms, comparing results against Povidone Iodine as a positive control.
Key findings
Comparable to Povidone Iodine. ACP demonstrated similar or better efficacy than the widely-used clinical disinfectant across multiple pathogen species.
Broad-spectrum coverage. High-efficacy results against gram-positive, gram-negative, anaerobic, and microaerophilic species, plus yeast isolates including Candida auris.
Effective against drug-resistant strains. ACP demonstrated efficacy against antibiotic-resistant ESKAPE pathogens where conventional agents may not be effective.
Efficacy increased with exposure time. Longer treatment durations showed progressively greater antimicrobial effect across all tested species.
"Because ACP was effective against some antibiotic resistant species, ACP may be effective in some settings where other antimicrobial agents will not be. This data suggests that ACP has unique clinical relevancy as a hand-held wound cleansing agent and decontamination device."
Dr. Jeffrey Shupp, MD · MedStar Health Research Institute
Burn Wound Healing Study
Three experiments examined ACP's effect on burn wound healing across deep partial thickness injuries, full thickness injuries with autografting, and full thickness injuries without grafting — simulating both hospital and austere field conditions.
Key findings
No negative impact on healing. ACP did not adversely affect healing trajectory in any of the three experiments — including grafted and ungrafted wounds.
Significant bioburden reduction. A significant decrease in bacterial bioburden was observed in treated wounds at Day 5, with a trend of lower bioburden continuing through Day 9.
Promising results for ungrafted wounds. Epidermis was present at Day 11 in plasma-treated ungrafted wounds with no epidermis visible in controls — particularly relevant for austere field conditions.
No adverse effects observed across tissue types. No adverse temperature fluctuations were observed in treated skin at standard treatment parameters. No adverse impacts to donor sites or uninjured normal skin were noted during the study period.
"Treatment that allows for reduction in bacteria while not being cytotoxic to host cells or impeding healing is desirable. ACP had no negative impact on healing in any of the experiments but did decrease bacterial bioburden — making it appealing for future clinical application in a variety of inpatient and outpatient settings."
Dr. Jeffrey Shupp, MD · MedStar Health Research Institute — Burn Wound Study Conclusion
Chemical Agent Decontamination Study
This study evaluated Aceso Plasma's ability to decontaminate surfaces exposed to VX, a highly toxic chemical warfare agent, at three treatment durations — establishing a baseline for future decontamination chamber development.
Key findings
Dose-dependent efficacy. VX reductions of 8.2% at 30 seconds, 25.9% at 60 seconds, and 47.5% at 240 seconds — demonstrating clear dose-response relationship.
Scalable with higher ROS concentration. Results support the development of a dedicated decontamination chamber that increases ROS density for enhanced efficacy.
Proof of concept for CBRNE applications. Establishes plasma-based decontamination as a viable approach for both biological and chemical warfare agent neutralization — supporting further development of a dedicated decontamination chamber form factor.
Published in leading
scientific journals.
The underlying plasma technology behind Aceso Plasma has been published in peer-reviewed journals by Dr. Spencer Kuo, Chief of Technology, providing an independent scientific foundation for the device's mechanism of action.
Applications of Air Plasma for Wound Bleeding Control and Healing
Key finding
In vivo porcine studies demonstrated that the air plasma spray shortens wound healing time to approximately half — from 14 days to 8 days — after a 10-second treatment application. The study also examined plasma effects on wound bleeding in animal models; these findings are from published peer-reviewed research and have not been substantiated in the current device's clinical development program.
Air Plasma for Medical Applications
Key finding
Comprehensive study establishing the design, emission characteristics, and medical applications of the handheld air plasma spray — including blood coagulation mechanism, bleeding control across four wound types, and post-operative wound healing observations.
Five institutions.
One consistent conclusion.
Each institution independently evaluated a different dimension of Aceso Plasma's capability — together forming a comprehensive, multi-disciplinary evidence base.
Wake Forest Institute of Regenerative Medicine
In vivo wound healing · Mouse model
MedStar Georgetown Research Institute
Antimicrobial efficacy · Burn wound healing
US Army CCDC CBC
Military field application validation
Edgewood Chemical Biological Center
Chemical warfare agent decontamination
NYU Tandon School of Engineering
Peer-reviewed plasma science research
Endorsed by those who've
served on the front lines.
Senior military physicians with combat deployment experience have evaluated Aceso Plasma and its potential to transform battlefield medicine.
The Aceso Plasma device is a revolutionary tool that controls massive hemorrhage, promotes wound healing, and rapidly sterilizes equipment. Its unique, durable, and intuitive design is invaluable for surgeons and medics alike, offering a novel solution that could change medicine on and off the battlefield.
The above reflects the personal opinion of Dr. Johnson based on his evaluation of the device. Hemostatic claims referenced in this testimonial have not been substantiated through controlled clinical studies and do not represent a cleared or approved indication of the device.
Dr. Ken Johnson, MD
Lieutenant Colonel, US Army · Bronze Star, Air Medal w/ V Device
If we had the Aceso Plasma device while I was serving as an Army Special Forces flight surgeon, we would have saved more lives on the front lines. Its ability to decontaminate and promote healing in austere environments using only electricity is game-changing. This device has the potential to be essential in every operating room and surgery center.
Dr. Tad Gerlinger, MD
Colonel, US Army (Ret.) · Bronze Star, Air Medal
Clinical trials are
beginning now.
Aceso Plasma is entering clinical trials at MedStar Georgetown Research Institute for chronic wounds and ESKAPE pathogen-infected wounds. We're looking for clinical partners and military collaborators to help bring this technology to market.
Aceso Plasma is an investigational device currently pending FDA clearance. All study conclusions referenced on this page are from SBIR Phase II-funded investigational research conducted at independent third-party institutions. This device is not currently cleared or approved for clinical use and is not available for sale.